COST-EFFECTIVENESS OF DOLUTEGRAVIR, A NEW GENERATION INTEGRASE INHIBITOR, IN HIV-1 TREATMENT EXPERIENCED PATIENTS IN FRANCE

被引：0
|
作者：
Despiegel, N. [1 ]
Marcellin, A. G. [2 ]
Aubin, C. [3 ]
Espinas, C. [1 ]
Laurisse, A. [4 ]
Pialoux, G. [5 ]
机构：
[1] Optum, Nanterre, France
[2] Hop La Pitie Salpetriere, AP HP, Paris, France
[3] GlaxoSmithKline, Marly Le Roi, France
[4] ViiV Healthcare France, Marly Le Roi, France
[5] Hop Tenon, AP HP, F-75970 Paris, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2526
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN85
引用
收藏
页码：A678 / A679
页数：3
相关论文
共 50 条
  • [1] Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France
    Pialoux, Gilles
    Marcelin, Anne-Genevieve
    Despiegel, Nicolas
    Espinas, Caroline
    Cawston, Helene
    Finkielsztejn, Laurent
    Laurisse, Audrey
    Aubin, Celine
    PLOS ONE, 2015, 10 (12):
  • [2] COST-EFFECTIVENESS OF DOLUTEGRAVIR/ABACAVIR/LAMIVUDINE IN HIV-1 TREATMENT NAIVE PATIENTS IN FRANCE
    Pialoux, G.
    Marcelin, A.
    Cawston, H.
    Guilmet, C.
    Laurisse, A.
    Finkielsztejn, L.
    Aubin, C.
    VALUE IN HEALTH, 2015, 18 (07) : A587 - A587
  • [3] Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada
    Despiégel N.
    Anger D.
    Martin M.
    Monga N.
    Cui Q.
    Rocchi A.
    Pulgar S.
    Gilchrist K.
    Refoios Camejo R.
    Infectious Diseases and Therapy, 2015, 4 (3) : 337 - 353
  • [4] Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France
    Pialoux, Gilles
    Marcelin, Anne-Genevieve
    Cawston, Helene
    Guilmet, Caroline
    Finkielsztejn, Laurent
    Laurisse, Audrey
    Aubin, Celine
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (01) : 83 - 91
  • [5] Dolutegravir, a Second-Generation Integrase Inhibitor for the Treatment of HIV-1 Infection
    Rathbun, R. Chris
    Lockhart, Staci M.
    Miller, Misty M.
    Liedtke, Michelle D.
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (03) : 395 - 403
  • [6] COST-EFFECTIVENESS OF DOLUTEGRAVIR IN HIV-1 TREATMENT-NAIVE PATIENTS IN RUSSIA
    Piercy, J.
    Jakubanis, R.
    Chounta, V
    Bukin, E.
    Kovalchuk, N.
    Punekar, Y. S.
    Holbrook, T.
    VALUE IN HEALTH, 2017, 20 (09) : A788 - A788
  • [7] New integrase inhibitor dolutegravir approved by US FDA for HIV-1 treatment
    McCarthy, Jacob
    FUTURE MICROBIOLOGY, 2013, 8 (10) : 1242 - 1243
  • [8] New integrase inhibitor dolutegravir approved by US FDA for HIV-1 treatment
    McCarthy, Jacob
    FUTURE VIROLOGY, 2013, 8 (10) : 945 - 946
  • [9] Dolutegravir: a new HIV integrase inhibitor for the treatment of HIV infection
    Max, Blake
    Vibhakar, Sonia
    FUTURE VIROLOGY, 2014, 9 (11) : 967 - 978
  • [10] Dolutegravir: A New Integrase Strand Transfer Inhibitor for the Treatment of HIV
    Shah, Bhavik M.
    Schafer, Jason J.
    DeSimone, Joseph A., Jr.
    PHARMACOTHERAPY, 2014, 34 (05): : 506 - 520
12345